Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting

Conditions: Hypogonadism, Male
NSCLC Stage IV
Sex Disorder
Erectile Dysfunction

Interventions: Drug: Alectinib
Drug: Osimertinib
Drug: Pembrolizumab
Drug: Cemiplimab
Drug: Brigatinib
Drug: Sotorasib
Drug: Lorlatinib 100 mg
Drug: Dabrafenib
Drug: Nivolumab
Drug: Trametinib
Drug: Carboplatin
Drug: Pemetrexed
Drug: Selpercatinib
Drug: Paclitaxel

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-09

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 80

Registration Number: NCT06532149

Locations: 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Brigatinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2024-07-26

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT06522360

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: BEBT-109 Capsules
Drug: Pemetrexed Disodium for Injection
Drug: Carboplatin Injection
Drug: Cisplatin Injection

First Posted Date: 2024-07-23

Last Posted Date: 2024-07-23

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 30

Registration Number: NCT06514027

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Phase 2

Not yet recruiting

Conditions: Small-cell Lung Cancer

Interventions: Drug: Intrathecal Pemetrexed

First Posted Date: 2024-07-11

Last Posted Date: 2024-08-02

Lead Sponsor: Hunan Province Tumor Hospital

Target Recruit Count: 80

Registration Number: NCT06497543

Locations: 🇨🇳
Yongchang Zhang, Changsha, Hunan, China

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Leptomeningeal Metastases

Interventions: Drug: Sacituzumab Govitecan
Drug: Pemetrexed

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-18

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 34

Registration Number: NCT06462092

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Biological: Sacituzumab Tirumotecan
Drug: Pemetrexed
Biological: Tisotumab Vedotin
Drug: Topotecan
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Irinotecan

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 686

Registration Number: NCT06459180

Locations: 🇺🇸
USA Mitchell Cancer Institute-Clinical Trials ( Site 4126), Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center ( Site 4137), Anchorage, Alaska, United States
🇺🇸
HonorHealth (HH) ( Site 8002), Phoenix, Arizona, United States

and more 205 locations

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 3

Recruiting

Conditions: Advanced Non-small Cell Lung Cancer
HER2 Mutation

Interventions: Drug: Pembrolizumab
Drug: BAY2927088
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2024-06-11

Last Posted Date: 2025-04-08

Lead Sponsor: Bayer

Target Recruit Count: 278

Registration Number: NCT06452277

Locations: 🇺🇸
Memorial Cancer Institute at Miramar, Miramar, Florida, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇧🇬
MHAT Sveta Marina EAD, Varna, Bulgaria

and more 264 locations